Drug Trial Radar · NCT06855277
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
940
Planned (sponsor's estimate)
Start
Jul 1, 2025
Primary completion
Sep 29, 2028
Study completion Nov 4, 2032
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether \[225Ac\]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of standard of care (SOC) (ARPI change or taxane-based chemotherapy or \[177Lu\]Lu-PSMA-617 (AAA617)) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC) treated with another ARPI as last treatment and who have not been exposed to a taxane-containing chemotherapy in the mCRPC setting nor have received any prior PSMA-targeting radioligand therapy.
Conditions
- Prostate Cancer
Interventions
AAA817Drug
AAA817 is being studied for treating PSMA positive mCRPC. Inside the body, it attaches itself to PSMA on the cell surface of the prostate cancer cells and emits radiation to kill them. This treatment is also called a radioligand therapy.
ARPIDrug
Androgen receptor pathway inhibitor (ARPI): An ARPI is approved for the treatment of prostate cancer. It works by blocking signals from male hormones, such as testosterone, that helps cancer cells grow. By blocking these signals, an ARPI slows down or stops the growth of prostate cancer cells. In this trial, participants will be given either enzalutamide or abiraterone.
Standard of CareDrug
Standard treatment includes approved treatment for mCRPC. In this trial, the trial doctor will decide which available treatment participants will receive. The trial doctor will select either an ARPI of enzalutamide or abiraterone, or a taxane based chemotherapy of docetaxel or cabazitaxel or \[177Lu\]Lu-PSMA-617 (AAA617).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression Free Survival (rPFS)Time frame: From the date of randomization to the date of the first documented radiographic disease progression using conventional imaging, or death due to any cause, whichever occurs first, assessed up to approximately 40.0 months.
Locations
106 sites in 12 countries. Site status is shown where the registry gives one.
Urology Centers Of Alabama Pc
Homewood, Alabama · Recruiting
University of Arizona
Tucson, Arizona · Recruiting
Univ Cali Irvine ALS Neuromuscular
Orange, California · Recruiting
Stanford University Medical Center
Palo Alto, California · Recruiting
Sansum Clinic
Santa Barbara, California · Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
Florida Cancer Specialists
Fort Myers, Florida · Recruiting
Baptist Health South
Miami, Florida · Recruiting
AdventHealth
Orlando, Florida · Recruiting
University Cancer and Blood Center LLC
Athens, Georgia · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Illinois Cancer Center at Chicago
Chicago, Illinois · Recruiting
Univ Of Iowa Hospitals And Clinics
Iowa City, Iowa · Recruiting
University of Kansas Hospital
Kansas City, Kansas · Recruiting
East Jefferson Hospital
Metairie, Louisiana · Recruiting
New England Cancer Specialists
Scarborough, Maine · Recruiting
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
Beth Israel Deaconess Med Center
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Wash U School of Medicine
St Louis, Missouri · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Astera Cancer Center
East Brunswick, New Jersey · Recruiting
New Jersey Urology LLC
Voorhees Township, New Jersey · Recruiting
New Mexico Oncology Hematology
Albuquerque, New Mexico · Recruiting
Bassett Medical Center
Cooperstown, New York · Recruiting
Weill Cornell Medicine NY-Presb
New York, New York · Recruiting
University of Rochester Medical Ctr
Rochester, New York · Recruiting
Associated Med Professionals of NY
Syracuse, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Urology Group - Solaris Network
Cincinnati, Ohio · Recruiting
Central Ohio Urology Group
Gahanna, Ohio · Recruiting
MUSC Hollings Cancer Center
Charleston, South Carolina · Recruiting
Carolina Urologic Research Center
Myrtle Beach, South Carolina · Recruiting
Tennessee Oncology PLLC
Chattanooga, Tennessee · Recruiting
Urology Austin
Lakeway, Texas · Recruiting
Urology San Antonio
San Antonio, Texas · Recruiting
Woodlands Cancer Institute American Oncology Partners
The Woodlands, Texas · Recruiting
Swedish Medical Center
Seattle, Washington · Recruiting
Northwest Medical Specialties
Tacoma, Washington · Recruiting
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.